8-K/A: Fate Therapeutics Amends Filing to Confirm Annual Executive Compensation Votes

Fate Therapeutics, Inc. has filed an amendment to its recent 8-K report, formally disclosing its decision to hold non-binding advisory votes on executive compensation annually, aligning with stockholder approval.

Summary

• Fate Therapeutics, Inc. filed an amended Current Report on Form 8-K/A on June 17, 2025.
• This amendment clarifies Item 5.07 of the original Form 8-K filed on May 30, 2025.
• The sole purpose of the amendment is to disclose the Company's decision regarding the frequency of future non-binding advisory votes to approve the compensation of its named executive officers.
• At the 2025 Annual Meeting of Stockholders held on May 29, 2025, stockholders approved, on a non-binding advisory basis, to hold these votes every one year.
• Consistent with this stockholder recommendation, the Board of Directors has determined to hold future non-binding advisory votes on executive compensation annually.
• The next advisory vote on the frequency of these votes is required to occur no later than the Company's 2031 annual meeting of stockholders.

Sentiment

Score: 7

Explanation: The document reflects a positive sentiment as the company is aligning its corporate governance practices with shareholder preferences, indicating good responsiveness and transparency.

Positives

• The company's Board of Directors is aligning its policy with the non-binding advisory vote of its stockholders regarding the frequency of executive compensation votes, demonstrating responsiveness to shareholder input.
• The decision to hold annual 'Say-on-Pay' votes enhances corporate governance and transparency.

Future Outlook

The company will hold future non-binding advisory votes to approve the compensation of its named executive officers annually. The next advisory vote on the frequency of these votes is mandated to occur no later than the 2031 annual meeting of stockholders.

Management Comments

• The Board has determined to hold future non-binding advisory votes to approve the compensation of the Company's named executive officers annually until the next advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the Company's named executive officers, which is required to occur no later than the Company's 2031 annual meeting of stockholders.

Industry Context

The practice of holding non-binding advisory votes on executive compensation, often referred to as 'Say-on-Pay' votes, is a standard corporate governance practice in the U.S., mandated by the Dodd-Frank Wall Street Reform and Consumer Protection Act. Companies typically hold these votes annually, biennially, or triennially, with annual votes being the most common and often preferred by institutional investors.

Comparison to Industry Standards

• Fate Therapeutics' decision to hold annual 'Say-on-Pay' votes aligns with the prevailing industry standard and best practices for corporate governance among publicly traded companies in the U.S.
• Many large institutional investors and proxy advisory firms advocate for annual Say-on-Pay votes, viewing them as a key mechanism for shareholder oversight of executive compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: Their advisory vote on the frequency of executive compensation reviews has been respected and implemented by the Board, enhancing their voice in corporate governance.
• Management: Executive compensation will be subject to annual non-binding advisory votes by shareholders, increasing accountability and transparency.

Next Steps

• The Company will continue to hold non-binding advisory votes on executive compensation annually.
• The next advisory vote on the frequency of these votes will occur no later than the Company's 2031 annual meeting of stockholders.

Key Dates

Keywords

Fate Therapeutics, SEC filing, 8-K/A, corporate governance, executive compensation, Say-on-Pay, stockholder vote, annual meeting, board of directors